替罗非班对急性冠脉综合征合并代谢综合征介入治疗患者的有效性及安全性研究-东南大学学报医学版

替罗非班对急性冠脉综合征合并代谢综合征介入治疗患者的有效性及安全性研究

单位：东南大学附属中大医院心内科, 江苏南京 210009

分类号：R543.3;R973

出版年·卷·期（页码）：2016·35·第五期（759-762）

摘要：

目的：探讨替罗非班对急性冠脉综合征（ACS）合并代谢综合征（MS）介入治疗患者的有效性及安全性。方法：选择2014年12月至2015年5月在东南大学附属中大医院心内科首次接受PCI治疗的ACS合并MS患者150例，根据术中及术后是否应用替罗非班，将患者分为替罗非班组（n=76）和对照组（n=74）。观察两组患者在住院期间以及PCI术后6个月的主要不良心血管事件（MACE）及住院期间出血事件发生率。结果：替罗非班组在住院期间MACE的发生率低于对照组（1.3% vs 10.8%，P=0.035）。替罗非班组在住院期间出血事件发生率与对照组相比差异无统计学意义（P>0.05）。随访6个月替罗非班组MACE发生率低于对照组（6.6% vs 17.6%，P=0.038）。结论：替罗非班可改善ACS合并MS介入治疗患者预后且具有良好安全性。

Objective: To investigate the tirofiban on efficacy and safety in patients with acute coronary syndrome(ACS)and metabolic syndrome(MS)after percutaneous coronary intervention. Methods: We selected 150 patients with ACS and MS undergoing PCI for the first time in the cardiology department of Zhongda hospital, between Dec 2014 and May 2015. According to whether or not tirofiban was used, we divided them into the tirofiban group(n=76)and the control group(n=74). The incidence of major adverse cardiovascular events(MACE)and bleeding events were observed in the two groups during hospitalization and 6 months after operation. Results: The incidence of MACE in the tirofiban group was lower than that of the control group during hospitalization(1.3% vs 10.8%, P=0.035). The was no statistical difference in the incidence of bleeding events in the two groups during hospitalization(P>0.05). The incidence of MACE in the tirofiban group was lower than that of the control group after 6 months follow-up(6.6% vs 17.6%, P=0.038). Conclusion: Tirofiban can improve the prognosis with higher safety in patients with ACS and MS after PCI.

参考文献：

[1] 孙同文,徐青艳,姚海木,等.代谢综合征对急性冠脉综合征PCI术预后的影响[J].中华急诊医学杂志,2012,21(10):1147-1152.
[2] 胡荣,马长生,聂绍平,等.代谢综合征可能比传统危险因素更能预测冠心病患者预后[J].中华医学杂志,2010,90(22):1537-1541.
[3] LEE D P,HERITY N A,HIATT B L,et al.Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes:results of the Tirofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA)pilot trial[J].Circulation,2003,107(11):1497-1501.
[4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,6(7):447-498.
[7] 董剑廷,袁勇,邓志华,等.代谢综合征患者冠状动脉病变特点的病例对照研究[J].中国基层医药,2005,12(10):1301-1302.
[8] 何胜虎,袁彬,陈述,等.盐酸替罗非班在老年急性冠状动脉综合征患者中的应用[J].中华急诊医学杂志,2009,18(8):826-830.
[9] 颜国荣,冯毅,章晓国,等.急诊经皮冠状动脉介入治疗中联合应用抽吸导管有效性的随访研究[J].现代医学,2012,40(1):25-29.
[10] LABINAZ M,HO C,BANERJEE S,et al.Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention[J].Can J Cardiol,2007,23(12):963-970.
[11] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS)Study Investigators[J].N Engl J Med,1998,338(21):1488-1497.
[12] VAN'T HOF A W,TEN BERG J,HEESTERMANS T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2):a multicentre,double-blind,randomised controlled trial[J].Lancet,2008,372(9638):537-546.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录